Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer
Verified date | May 2023 |
Source | Masonic Cancer Center, University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
Status | Completed |
Enrollment | 6 |
Est. completion date | February 28, 2022 |
Est. primary completion date | February 28, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria - Recurrent or progressive advanced stage non-small cell lung cancer (no small cell component) with most recent treatment being an FDA approved immune checkpoint inhibitor (pembrolizumab, atezolizumab, or nivolumab) NOTE: Pathology reports documenting the diagnosis of NSCLC are required to be reviewed to confirm outside diagnosis - Sufficient tumor tissue available from original diagnosis or subsequent biopsy for analysis of estrogen receptor and aromatase - tumor block or a minimum of 5 unstained slides - Failed at least 1 prior FDA approved treatment for advanced NSCLC. Patients with EGFR/ALK/ROS1 rearrangements should have received an FDA-approved TKI prior to enrollment on this trial. - Measureable disease by RECIST version 1.1 - Post-menopausal defined as - Age = 55 years and 1 year or more of amenorrhea - Age < 55 years and 1 year or more of amenorrhea with an estradiol assay < 20 pg/mL - Surgical menopause with bilateral oophorectomy - ECOG performance status 0, 1 or 2 * Life expectancy of 3 months or more in the opinion of the enrolling investigator and documented in the medical record - Adequate organ function within 14 days of study enrollment defined as: - Hematology: ** Absolute neutrophil count (ANC) = 1500/mm³, Platelets = 100,000/mm³, Hemoglobin = 8 g/dL - Biochemistry: - Total Bilirubin within normal institutional limits - AST/SGOT and ALT/SGPT = 2.5 x upper limit of normal (ULN), except if there is known hepatic metastasis, wherein transaminases may be = 5 x institutional ULN. - Serum creatinine = 1.5 mg/dl or glomerular filtration rate > 50 ml/min - Must have recovered to CTCAE v 4 Grade 1 or better from the acute effects of any prior surgery, chemotherapy or radiation therapy. Chronic residual toxicity (i.e. peripheral neuropathy) is permitted. - A minimum time period must elapse between the end of a previous treatment and start of study therapy: - 1 week from the completion of radiation therapy for brain metastases - 4 weeks from the completion of chemotherapy or any experimental therapy - 4 weeks from prior major surgery (such as open biopsy or significant traumatic injury) - Voluntary written consent before any research related procedures or therapy Exclusion Criteria - Known active CNS disease - If patient has history of brain metastases, the brain lesions must have been treated with radiation and/or surgery - patients should be neurologically stable and requiring =10mg oral prednisone equivalence of steroids per day - Any toxicity from immune-related toxicity from prior immune therapy that would preclude further treatment with anti-PD-1/PDL-1 inhibitor or ongoing IR toxicity = Grade 2 - Requiring > 10 mg prednisone equivalence of steroids per day for immune-related toxicity - Inability or unwilling to swallow study drug - Any gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome) - Currently using hormone replacement therapy (oral or patch) or/and phytoestrogen supplements (i.e. black cohosh) - Known hypersensitivity to exemestane or its excipients - Any serious underlying medical condition that, in the opinion of the enrolling physician, would impair the ability of the patient to receive protocol treatment - Prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a 3-year disease-free interval - Concomitant use of strong CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's wort as these may significantly reduce the availability of exemestane |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic Health System | Albert Lea | Minnesota |
United States | Essentia Health St. Joseph's Medical Center | Brainerd | Minnesota |
United States | Essentia Health Deer River | Deer River | Minnesota |
United States | Essentia Health St. Mary's Detroit Lakes | Detroit Lakes | Minnesota |
United States | Essentia Health Cancer Center | Duluth | Minnesota |
United States | Essentia Health Fosston | Fosston | Minnesota |
United States | Fairview Grand Itasca Clinic & Hospital | Grand Rapids | Minnesota |
United States | Essentia Health Hibbing | Hibbing | Minnesota |
United States | Fairview Range Medical Center | Hibbing | Minnesota |
United States | Mayo Clinic Health System | Mankato | Minnesota |
United States | Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota |
United States | Monticello Cancer Center (MMCORC) | Monticello | Minnesota |
United States | Essentia Health Park Rapids | Park Rapids | Minnesota |
United States | Fairview Northland Medical Center | Princeton | Minnesota |
United States | Essentia Health Sandstone | Sandstone | Minnesota |
United States | Sanford Thief River Falls Medical Center | Thief River Falls | Minnesota |
United States | Essentia Health Virginia | Virginia | Minnesota |
United States | Sanford Worthington Medical Center | Worthington | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Masonic Cancer Center, University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease Response (RECIST) | Initial disease response will be assessed from 6 weeks to 1 year after the start of exemestane using the Response Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | 6 weeks | |
Secondary | Toxicity Assessment | Toxicity will be assessed from the 1st dose to Post Treatment Day 30, up to 22 weeks. Toxicity severity will be graded using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4. | Post Treatment Day 30 | |
Secondary | Progression-free Survival | progression-free survival will be assessed until 1 year after study enrollment based on the definitions found in RECIST 1.1 | 1 year after enrollment | |
Secondary | Quality of Life Assessment | Quality of life will be assessed by use of Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) at baseline, every 3 weeks from the 1st dose to Post Treatment Day 30, up to 22 weeks. Patient's report on a number of subjects on a 0-10 scale. The scores range from 28 to 150. 50 is the average score, 28 is the best health and 150 is the worst health. | Baseline, Treatment, End of Treatment, and 1 Month Post-Treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |